Brief: Selecta Biosciences Announces Partnership Advancements And Clinical Trial Updates

Cartesian Therapeutics

13/06/2022 12:36

June 13 (Reuters) - Selecta Biosciences Inc  SELB.O :
    * SELECTA BIOSCIENCES ANNOUNCES PARTNERSHIP ADVANCEMENTS AND
CLINICAL TRIAL UPDATES
    * SELECTA - SAREPTA EXTENDS RESEARCH LICENSE AND OPTION
AGREEMENT
FOR IMMTOR IN DUCHENNE MUSCULAR DYSTROPHY AND CERTAIN
LIMB-GIRDLE MUSCULAR DYSTROPHIES
    * SELECTA BIOSCIENCES INC - SELECTA TO RECEIVE A $2 MILLION
PAYMENT FROM SAREPTA EXTENDING THEIR OPTION PERIODS UNDER
AGREEMENT TO Q1 2023
    * SELECTA - ENROLLMENT IN DISSOLVE II CONTINUES TO ADVANCE
WITH
FULL ENROLLMENT ANTICIPATED BY END OF Q2 2022
    * SELECTA BIOSCIENCES INC - DISSOLVE I & II STUDIES REMAIN
ON
TRACK FOR COMPLETION IN Q4 2022 WITH JOINT TOPLINE DATA IN Q1
2023

Source text for Eikon:  ID:nGNXdnCy2 
Further company coverage:  SELB.O 

 ((Reuters.Briefs@thomsonreuters.com;))